| Details |
title |
year |
| Details |
#1253 Dissecting the signaling cascades involved in growth inhibition and a... |
2018 |
| Details |
#2813 Effcacy and pharmacokinetics of niraparib in BRCA -mutant and wild-t... |
2018 |
| Details |
EXPERIMENTAL AND MOLECULAR THERAPEUTICS: Modulation of DNA Damage and Repai... |
2018 |
| Details |
#4616 Cancer-associated MUC1 epitope-recognizing antibody as a novel immuno... |
2018 |
| Details |
#3640 Treatment strategies using anti-PD1/PD-L1 (anti-PD) and BRAF/ MEK inh... |
2018 |
| Details |
-catenin signaling pathway.... |
2018 |
| Details |
TUMOR BIOLOGY: Radiation Studies Using in Vivo and Clinical Models... |
2018 |
| Details |
MOLECULAR AND CELLULAR BIOLOGY / GENETICS: BCL-2 Family and Mitochondrial A... |
2018 |
| Details |
#572 Genome-scale CRISPR/Cas9 screen identifes factors required for sensiti... |
2018 |
| Details |
#1616 Novel caged hapten proximity assay platform enables detection of onco... |
2018 |
| Details |
#3184 A secondary mutation in BRAF confers resistance to RAF inhibi- tion... |
2018 |
| Details |
EXPERIMENTAL AND MOLECULAR THERAPEUTICS: Combination Chemotherapy 2 #5805 P... |
2018 |
| Details |
#3216 H2AX is a novel prognostic marker of breast cancer.... |
2018 |
| Details |
#2452 Dysregulated expression of the human long noncoding RNA GH- SROS ma... |
2018 |
| Details |
#4762 Clinicopathologic fndings of borderline resectable pancreatic cancer ... |
2018 |
| Details |
#4008 Activating HER2 (ERBB2 ) mutations lead to endocrine therapy resista... |
2018 |
| Details |
TUMOR BIOLOGY: Carcinogenesis 3... |
2018 |
| Details |
CANCER CHEMISTRY: Molecules Addressing Challenges in Drug Discovery... |
2018 |
| Details |
#944 Glucocorticoid receptor (GR)-mediated activation of cyclic-adeno- sine... |
2018 |
| Details |
#430 Detection of low-frequency variants from highly degraded DNA samples u... |
2018 |